Literature DB >> 27208331

Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home.

Eric Renard1, Anne Farret2, Jort Kropff3, Daniela Bruttomesso4, Mirko Messori5, Jerome Place2, Roberto Visentin6, Roberta Calore6, Chiara Toffanin5, Federico Di Palma5, Giordano Lanzola7, Paolo Magni7, Federico Boscari4, Silvia Galasso4, Angelo Avogaro4, Patrick Keith-Hynes8, Boris Kovatchev8, Simone Del Favero6, Claudio Cobelli6, Lalo Magni5, J Hans DeVries3.   

Abstract

OBJECTIVE: After testing of a wearable artificial pancreas (AP) during evening and night (E/N-AP) under free-living conditions in patients with type 1 diabetes (T1D), we investigated AP during day and night (D/N-AP) for 1 month. RESEARCH DESIGN AND METHODS: Twenty adult patients with T1D who completed a previous randomized crossover study comparing 2-month E/N-AP versus 2-month sensor augmented pump (SAP) volunteered for 1-month D/N-AP nonrandomized extension. AP was executed by a model predictive control algorithm run by a modified smartphone wirelessly connected to a continuous glucose monitor (CGM) and insulin pump. CGM data were analyzed by intention-to-treat with percentage time-in-target (3.9-10 mmol/L) over 24 h as the primary end point.
RESULTS: Time-in-target (mean ± SD, %) was similar over 24 h with D/N-AP versus E/N-AP: 64.7 ± 7.6 vs. 63.6 ± 9.9 (P = 0.79), and both were higher than with SAP: 59.7 ± 9.6 (P = 0.01 and P = 0.06, respectively). Time below 3.9 mmol/L was similarly and significantly reduced by D/N-AP and E/N-AP versus SAP (both P < 0.001). SD of blood glucose concentration (mmol/L) was lower with D/N-AP versus E/N-AP during whole daytime: 3.2 ± 0.6 vs. 3.4 ± 0.7 (P = 0.003), morning: 2.7 ± 0.5 vs. 3.1 ± 0.5 (P = 0.02), and afternoon: 3.3 ± 0.6 vs. 3.5 ± 0.8 (P = 0.07), and was lower with D/N-AP versus SAP over 24 h: 3.1 ± 0.5 vs. 3.3 ± 0.6 (P = 0.049). Insulin delivery (IU) over 24 h was higher with D/N-AP and SAP than with E/N-AP: 40.6 ± 15.5 and 42.3 ± 15.5 vs. 36.6 ± 11.6 (P = 0.03 and P = 0.0004, respectively).
CONCLUSIONS: D/N-AP and E/N-AP both achieved better glucose control than SAP under free-living conditions. Although time in the different glycemic ranges was similar between D/N-AP and E/N-AP, D/N-AP further reduces glucose variability.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27208331     DOI: 10.2337/dc16-0008

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  31 in total

Review 1.  Multivariable Adaptive Artificial Pancreas System in Type 1 Diabetes.

Authors:  Ali Cinar
Journal:  Curr Diab Rep       Date:  2017-08-15       Impact factor: 4.810

2.  The UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day.

Authors:  Roberto Visentin; Enrique Campos-Náñez; Michele Schiavon; Dayu Lv; Martina Vettoretti; Marc Breton; Boris P Kovatchev; Chiara Dalla Man; Claudio Cobelli
Journal:  J Diabetes Sci Technol       Date:  2018-02-16

Review 3.  Artificial Pancreas: Current Progress and Future Outlook in the Treatment of Type 1 Diabetes.

Authors:  Rozana Ramli; Monika Reddy; Nick Oliver
Journal:  Drugs       Date:  2019-07       Impact factor: 9.546

4.  Hypoglycemia Prevention via Personalized Glucose-Insulin Models Identified in Free-Living Conditions.

Authors:  Chiara Toffanin; Eleonora Maria Aiello; Claudio Cobelli; Lalo Magni
Journal:  J Diabetes Sci Technol       Date:  2019-10-23

5.  Randomized Controlled Trial of Mobile Closed-Loop Control.

Authors:  Boris Kovatchev; Stacey M Anderson; Dan Raghinaru; Yogish C Kudva; Lori M Laffel; Carol Levy; Jordan E Pinsker; R Paul Wadwa; Bruce Buckingham; Francis J Doyle; Sue A Brown; Mei Mei Church; Vikash Dadlani; Eyal Dassau; Laya Ekhlaspour; Gregory P Forlenza; Elvira Isganaitis; David W Lam; John Lum; Roy W Beck
Journal:  Diabetes Care       Date:  2020-01-14       Impact factor: 19.112

6.  Improving Glucose Prediction Accuracy in Physically Active Adolescents With Type 1 Diabetes.

Authors:  Nicole Hobbs; Iman Hajizadeh; Mudassir Rashid; Kamuran Turksoy; Marc Breton; Ali Cinar
Journal:  J Diabetes Sci Technol       Date:  2019-01-18

Review 7.  Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.

Authors:  David Rodbard
Journal:  Diabetes Technol Ther       Date:  2017-06       Impact factor: 6.118

8.  The International Diabetes Closed-Loop Study: Testing Artificial Pancreas Component Interoperability.

Authors:  Stacey M Anderson; Eyal Dassau; Dan Raghinaru; John Lum; Sue A Brown; Jordan E Pinsker; Mei Mei Church; Carol Levy; David Lam; Yogish C Kudva; Bruce Buckingham; Gregory P Forlenza; R Paul Wadwa; Lori Laffel; Francis J Doyle; J Hans DeVries; Eric Renard; Claudio Cobelli; Federico Boscari; Simone Del Favero; Boris P Kovatchev
Journal:  Diabetes Technol Ther       Date:  2019-01-16       Impact factor: 6.118

9.  Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial.

Authors:  Boris P Kovatchev; Laura Kollar; Stacey M Anderson; Charlotte Barnett; Marc D Breton; Kelly Carr; Rachel Gildersleeve; Mary C Oliveri; Christian A Wakeman; Sue A Brown
Journal:  Lancet Digit Health       Date:  2020-01-03

10.  Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide.

Authors:  Jennifer L Sherr; Neha S Patel; Camille I Michaud; Miladys M Palau-Collazo; Michelle A Van Name; William V Tamborlane; Eda Cengiz; Lori R Carria; Eileen M Tichy; Stuart A Weinzimer
Journal:  Diabetes Care       Date:  2016-05-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.